Teva Pharmaceutical Industries ADR (TEVA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2010 | 12-2009 | 12-2008 | 12-2007 | 12-2006 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 3,339,000 | 2,004,000 | 635,000 | 1,952,000 | 546,000 |
| Depreciation Amortization | 977,000 | 908,000 | 493,000 | 521,000 | 431,000 |
| Income taxes - deferred | -199,000 | -140,000 | N/A | N/A | N/A |
| Accounts receivable | 55,000 | -150,000 | N/A | N/A | N/A |
| Other Working Capital | -205,000 | 445,000 | 76,000 | -854,000 | -218,000 |
| Other Operating Activity | 169,000 | 306,000 | 2,027,000 | 194,000 | 1,299,000 |
| Operating Cash Flow | $4,136,000 | $3,373,000 | $3,231,000 | $1,813,000 | $2,058,000 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -10,000 | -448,000 | -681,000 | -542,000 | -390,000 |
| Net Acquisitions | -4,951,000 | N/A | -4,749,000 | -18,000 | -3,587,000 |
| Purchase Of Investment | -436,000 | -433,000 | N/A | N/A | N/A |
| Other Investing Activity | -58,000 | -35,000 | 1,293,000 | -793,000 | -81,000 |
| Investing Cash Flow | $-5,455,000 | $-916,000 | $-4,137,000 | $-1,353,000 | $-4,058,000 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | 626,000 | -2,002,000 | N/A | N/A | N/A |
| Debt Issued | 2,537,000 | 445,000 | N/A | N/A | N/A |
| Debt Repayment | -2,017,000 | -325,000 | N/A | N/A | N/A |
| Common Stock Issued | 180,000 | 169,000 | N/A | N/A | N/A |
| Common Stock Repurchased | -99,000 | N/A | N/A | N/A | N/A |
| Dividend Paid | -668,000 | -529,000 | -388,000 | -299,000 | -229,000 |
| Other Financing Activity | 14,000 | -23,000 | 1,746,000 | -63,000 | 2,253,000 |
| Financing Cash Flow | $573,000 | $-2,265,000 | $1,358,000 | $-362,000 | $2,024,000 |
| Exchange Rate Effect | -1,000 | -51,000 | -86,000 | 58,000 | 32,000 |
| Beginning Cash Position | 1,995,000 | 1,854,000 | 1,488,000 | 1,332,000 | 1,276,000 |
| End Cash Position | 1,248,000 | 1,995,000 | 1,854,000 | 1,488,000 | 1,332,000 |
| Net Cash Flow | $-747,000 | $141,000 | $366,000 | $156,000 | $56,000 |
| Free Cash Flow | |||||
| Operating Cash Flow | 4,136,000 | 3,373,000 | 3,231,000 | 1,813,000 | 2,058,000 |
| Capital Expenditure | -710,000 | -719,000 | N/A | N/A | N/A |
| Free Cash Flow | 3,426,000 | 2,654,000 | 3,231,000 | 1,813,000 | 2,058,000 |